The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus
Authors:
- Jan BalanskyJBJan Balansky
- Kenneth PfarrKPKenneth Pfarr
- Christiane SzekatCSChristiane Szekat
- Stefan KehrausSKStefan Kehraus
- Tilman AdenTATilman Aden
- Miriam GrosseMGMiriam Grosse
- Rolf JansenRJRolf Jansen
- Thomas HesterkampTHThomas Hesterkamp
- Andrea SchieferASAndrea Schiefer
- Gabriele M. KönigGKGabriele M. König
- Marc StadlerMarc Stadler
- Achim HoeraufAchim Hoerauf
Open Access
- 8 July 2022
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 11 (7) , 920
Abstract
Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S. aureus using fluctuation analysis at 4 × minimum inhibitory concentration (MIC). Resistant mutants were characterized. S. aureus strains HG001, Mu50, N315, and USA300 had an MIC of 0.25 mg/L. The median FoM for CorA resistance was 1.5 × 10−8, 4.5-fold lower than the median FoM of 6.7 × 10−8 for rifampicin, and was reflected in a 4-fold lower mutation rate for CorA than rifampicin (6 × 10−9 for CorA vs. 2.5 × 10−8 for rifampicin). In CorA-resistant/rifampicin-sensitive strains, the majority of amino acid exchanges were S1127L in RpoB or K334N in RpoC. S. aureus Mu50, a rifampicin-resistant clinical isolate, yielded two further exchanges targeting amino acids L1131 and E1048 of the RpoB subunit. The plating of >1011 cells on agar containing a combination of 4 × MIC of rifampicin and 4 × MIC of CorA did not yield any growth. In conclusion, with proper usage, e.g., in combination therapy and good antibiotic stewardship, CorA is a potential antibiotic for treating S. aureus infections.Keywords
Funding Information
- The German Center for Infection Research (DZIF) (#09.807, #09.806, 16GW0227K)
- Bundesministerium für Forschung, Technologie und Raumfahrt (#09.807, #09.806, 16GW0227K)
This publication has 20 references indexed in Scilit:
- Frequency, Spectrum, and Nonzero Fitness Costs of Resistance to Myxopyronin in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2012
- Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence dataBioinformatics, 2012
- Activity of and Development of Resistance to Corallopyronin A, an Inhibitor of RNA PolymeraseAntimicrobial Agents and Chemotherapy, 2011
- Repair of Global Regulators inStaphylococcus aureus8325 and Comparative Analysis with Other Clinical IsolatesInfection and Immunity, 2010
- Fluctuation AnaLysis CalculatOR: a web tool for the determination of mutation rate using Luria–Delbrück fluctuation analysisBioinformatics, 2009
- Transcription inactivation through local refolding of the RNA polymerase structureNature, 2008
- The RNA Polymerase “Switch Region” Is a Target for InhibitorsCell, 2008
- Molecular Genetic and Structural Modeling Studies of Staphylococcus aureus RNA Polymerase and the Fitness of Rifampin Resistance Genotypes in Relation to Clinical PrevalenceAntimicrobial Agents and Chemotherapy, 2006
- Myxopyronin B analogs as inhibitors of RNA polymerase, synthesis and biological evaluationBioorganic & Medicinal Chemistry Letters, 2004
- The corallopyronins, new inhibitors of bacterial RNA synthesis from Myxobacteria.The Journal of Antibiotics, 1985